BCBS

Changes in capital requirements were supposed to make clearing OTC derivatives through central counter-parties a no-brainer. However, research by the US’s Office of Financial Research has found that the case for centralised clearing on a cost basis is somewhat more ambiguous.

Global Risk Regulator’s articles are exclusively

available to full subscribers

 

Subscribe today to ensure you stay informed about the latest global regulations and standards.

Tel: +44 (0)20 7873 3183
Email: grr@ft.com

Global Risk Regulator
   
Subscribing to Global Risk Regulator ensures easy online access and navigation for the latest analysis, multimedia content, monthly and breaking news alerts straight to your inbox and access to the 10-year archive.
 
Navigate through the regulatory landscape with a subscription to Global Risk Regulator.